Comparative Pharmacology
Head-to-head clinical analysis: UNASYN versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNASYN versus VEETIDS.
UNASYN vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic